Minimally invasive nephrolithotomy versus retrograde intrarenal surgery in surgical management of Lower calyceal stones: a systematic review with meta-analysis

Author:

Liu Ming1,Hou Jun2,Xu FeiHong2,Du HuiFang2,Liu JingXuan2ORCID,Li Ning2

Affiliation:

1. Operations and Performance Management Office, Fourth Affiliated Hospital, China Medical University, Shenyang, Liaoning, China

2. Urology

Abstract

Objective: The efficacy and safety of minimally invasive nephrolithotomy (MPCNL) versus retrograde intrarenal surgery (RIRS) was assessed for lower calyceal (LC) stones. Methods: Our team conducted a systematic literature search up to December, 2022, using PUBMED, EMBASE and the Cochrane Library. The study was registered in PROSPERO, CRD 42021247197. Randomized controlled trials evaluating the efficacy and safety of MPCNL versus RIRS for LC stones were collected. Heterogeneity among the studies was assessed using the χ2 test based on the Q and I 2 tests. Pooled effect sizes were calculated using a fixed model if I 2 is less than 50%; otherwise, a random-effects model was chosen. The primary outcomes were the 3-month stone-free rate (3SFR) and total complications, while the secondary outcomes were the operating time, hospital stay, haemoglobin reduction, bleeding, postoperative fever and complications with the Clavien–Dindo system. A subgroup analysis of 10–20 mm LC stones was also designed. Results: A total of 7 peer-reviewed trials comprising 711 patients were identified. No statistical differences were observed in the heterogeneity results of the 3SFR or total complications (P>0.1, I 2 < 50%). Compared with RIRS, MPCNL had an unfavourable safety profile, resulting in total complications [odds ratio (OR): 1.87 (95% CI: 1.05, 3.33); P=0.03], haemoglobin reduction [OR: 0.81 (95% CI: 0.15, 1.47); P=0.02] and complications with Grade I [OR: 5.52 (95% CI: 1.34, 22.83); P=0.02] but an improved efficacy and 3SFR [OR: 2.43 (95% CI: 1.48, 3.97); P=0.0004]. As for the 10–20 mm LC stones, compared with RIRS, MPCNL also had an unfavourable safety profile, resulting in total complications [OR: 2.47 (95% CI: 1.20, 5.07); P=0.01], complications with Grade I [OR: 4.97 (95% CI: 0.99, 25.01); P=0.05] and an increased hospital stay [OR: 2.46 (95% CI: 2.26, 2.66); P=0.00001] but an improved efficacy and 3SFR {OR: 3.10 (95% CI: 1.61, 5.99); P=0.0008]. The efficacy effect of MPCNL and safety effect of RIRS were nearly equal for both stones sized less than 20 mm (number needed to treat = 17, number needed to harm = 20) and stones sized 10–20 mm (number needed to treat = 20, number needed to harm = 13). No statistical difference was found between the MPCNL and RIRS groups for the rest of outcomes. Conclusion: Both MPCNL and RIRS are safe and effective management methods. Moreover, compared with RIRS, MPCNL had an unfavourable safety profile but improved efficacy for LC stones of ≤20 mm or 10–20 mm, and the differences were statistically significant. The relative profit of efficacy of MPCNL was similar to the relative profit of safety of RIRS.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,Surgery

Reference28 articles.

1. EAU Guidelines on Interventional Treatment for Urolithiasis;Türk;Eur Urol,2016

2. The incidence of lower-pole nephrolithiasis—increasing or not?;Cass;Br J Urol,1998

3. Optimal management of lower pole stones: the direction of future travel;Moore;Cent Eur J Urol,2016

4. Percutaneous nephrolithotomy: update, trends, and future directions;Ghani;Eur Urol,2016

5. Durability of flexible ureteroscopes: a randomized, prospective study;Monga;J Urol,2006

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3